Previous 10 | Next 10 |
2023-07-26 08:45:24 ET Palm Beach, FL – July 26, 2023 – FinancialNewsMedia.com News Commentary – Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming yea...
(NewsDirect) By Rachael Green, Benzinga The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. Slated to take effect starting in 2024, the new temporary CPT III c...
--News Direct-- By Rachael Green, Benzinga The American Medical Association’s (AMA) Panel recently released the full details of a new code for psychological support during the administration of psychedelic treatments. Slated to take effect starting in 2024, the new temporary CPT II...
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in Nature Medicine that demon...
A new study has attempted to explore how people on antidepressants such as Lexapro (escitalopram) and psilocybin process emotions on a neural level. The researchers behind the recent study wanted to analyze how people process their emotions when under the influence of psilocybin compared with Lex...
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 LONDON, July 17, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“C...
2023-07-16 18:00:00 ET Summary Alex Carchidi returns to update investors on the psychedelics industry. Collapse, consolidation, and why you shouldn't bet on just 1 stock. Compass Pathways' timeline for clinical trials; Atai and Cybin's recent wins. Alex Carchidi For ...
2023-07-15 18:06:24 ET Psychedelic stocks have taken it on the chin lately, with equity prices way down. Investors will have to be nimble and focus on individual stock picking, according to analyst Alex Carchidi. Speaking on Seeking Alpha's Investing Experts podcast, Carchi...
2023-07-14 19:10:45 ET Summary A review of recent research suggests that the testing methods may have led to overly optimistic expectations. A competitive drug has been approved and appears to be making excellent commercial headway. COMPASS Pathways is short on cash but has ma...
2023-07-13 12:35:00 ET Summary Will tough times continue for psychedelic stocks? Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways, Atai and Cybin. Inevitability of big pharma entering the space. Listen below or on the g...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...